TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04489316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrative medicine curriculum
Description: The curriculum will consist of three sessions in narrative medicine- i.e. discussing texts and poetry, and engaging in reflective writing as a group
Study: NCT05131945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Suction Thoracentesis
Description: a procedure that removes excess fluid from the space in between your lungs and chest wall

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Suction Thoracentesis
Description: a procedure that removes excess fluid from the space in between your lungs and chest wall

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gravity Thoracentesis
Description: a procedure that removes excess fluid from the space in between your lungs and chest wall

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gravity Thoracentesis
Description: a procedure that removes excess fluid from the space in between your lungs and chest wall
Study: NCT02439853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly Check-in Session
Description: Subjects in the Check-In group will have an online session with a speech-language pathologist 3-, 4-, and 5-months from the subject's enrollment date.
Study: NCT01705119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standing
Study: NCT03035032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Subcutaneous Injection
Study: NCT01183260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trabecular Metal Revision Cup
Description: Revision of the acetabular cup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trabecular Metal Modular Cup
Description: Revision of the acetabular cup
Study: NCT03716180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab works by targeting the HER2/neu receptor on cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab is a monoclonal antibody which targets the surface of the cells human epidermal growth factor receptor 2 protein (HER2) on the cancer cell, interfering with HER2 causing cancer cell death
Study: NCT00746681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine & Pregabalin
Description: Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: Tolterodine SR, Oral, 4 mg, once daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Oral, twice daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine & Pregabalin
Description: Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin, Oral, 150 mg twice daily for 4 weeks
Study: NCT01953640

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03864783

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin (Meriva®)
Description: Experimental drug:~Meriva® 500 mg tablet (contains 1 mg curcumin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo:~Contains same ingredients as Meriva®, apart from curcumin. Similar in appearance to Meriva®.
Study: NCT04040764

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tritanium uncemented Total Knee Replacement
Description: This will be an internal pilot study in which patients will be blinded and randomly assigned to 1 of 2 arms with 30 patients in each arm. The first arm will receive a Triathlon knee replacement device which is cemented into place. The second arm will receive an uncemented Triathlon Tritanium TKR.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tritanium uncemented Total Knee Replacement
Description: This will be an internal pilot study in which patients will be blinded and randomly assigned to 1 of 2 arms with 30 patients in each arm. The first arm will receive a Triathlon knee replacement device which is cemented into place. The second arm will receive an uncemented Triathlon Tritanium TKR.
Study: NCT03381690

Intervention type: PROCEDURE
Intervention: Epidural labor analgesia
Description: Epidural catheter was inserted for labor analgesia using an 18-gauge Tuohy needle and a 20 gauge epidural catheter. In our institute, for epidural labor analgesia, 10 ml bolus of 0.075% levobupivacaine mixed with fentanyl 2 μg/ml was administered and same regimen was continuously infused by patient-controlled epidural analgesia (infusion rate : 10 ml/hr, bolus : 4 ml, lockout time: 30 min).
Study: NCT02678949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Fluticasone 50 mcg/twice day
Description: After 7 days washout period, patients with mild asthma (group 2) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone 50 mcg/twice a day, for a period of 4 weeks. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Fluticasone 100 mcg/twice day
Description: After 7 days washout period, patients with moderate asthma (group 3) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone of 100 mcg/twice a day, for 4 weeks period. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Albuterol
Description: The patients in Group 2 and group 3 performing a baseline spirometry and MBW test, after which one dose of 400 mcg of inhaled albuterol will be administered. Twenty minutes after inhaling the dose of albuterol, spirometry and MBW test will be measured again in both groups.
Study: NCT03603782

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2.5% protein
Description: 2.5%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2.5% protein
Description: 2.5%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2.5% protein
Description: 2.5%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein 5%
Description: 5%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein 5%
Description: 5%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein 5%
Description: 5%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein 10%
Description: 10%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein 10%
Description: 10%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein 10%
Description: 10%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein 15%
Description: 15%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein 15%
Description: 15%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein 15%
Description: 15%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A2: Peptamen 1.5 Vanilla without Breakfast
Description: Peptamen withoug breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A2: Peptamen 1.5 Vanilla without Breakfast
Description: Peptamen withoug breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A2: Peptamen 1.5 Vanilla without Breakfast
Description: Peptamen withoug breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B2: only breakfast (no product)
Description: only breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B2: only breakfast (no product)
Description: only breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B2: only breakfast (no product)
Description: only breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C2: 5% protein with breakfast
Description: C2: 5% protein consumed with breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C2: 5% protein with breakfast
Description: C2: 5% protein consumed with breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C2: 5% protein with breakfast
Description: C2: 5% protein consumed with breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D2: 5% protein 30 min before breakfast
Description: D2: 5% protein consumed 30 min before breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D2: 5% protein 30 min before breakfast
Description: D2: 5% protein consumed 30 min before breakfast
Study: NCT03787056

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draws
Description: Blood draws are realized at each steps of patient disease management. The volume of each blood drawn is 25 mL for progastrin measurements and 5 mL for the dosage of the other tumor markers. The frequency depend to the cancer and treatment administered :~* Baseline at diagnosis : Local radical treatment : within 24h before surgery, within 24h after surgery and at the post-surgery follow up visit~* Chemotherapy treatment : every 3 or 4 weeks~* Radiotherapy : start day and at the end of radiation (end of treatment visit)~* Palliative systemic treatment (only palliative cohorts) : every 3 to 12 weeks. Follow until the third progression or change of treatment line, or alternatively up to 5 years after inclusion~* In case of PD or TOX~* Follow up: at each visit scheduled (every 3 months) for the first 2 years, then every 6 months for 3 years~* Relapse : withdrawn from the study and last progastrin measurement. Patient could be enrolled in the non-curative intent cohort
Study: NCT00306670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: Acquired Hemophilia A Patients Who Have Developed Anti-Factor VIII Antibodies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: \<30 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: \<30 mg/day
Study: NCT05871567

Intervention type: PROCEDURE
Intervention: colorectal resection
Description: potential resective surgery

Intervention type: PROCEDURE
Intervention: colorectal resection
Description: potential resective surgery
Study: NCT03454698

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Usual care as described for the CG also applies to the IG. The intervention will consist of giving patients an opportunity to learn about the use of compression bandages, wearing and putting on compression stockings, physical activity, good skin care, and a high-protein, vitamin-rich diet. This group will be supervised by a study nurse, who will not be identical with the nurse in charge of the control group.
Study: NCT01827475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen-acetaminophen combination
Description: single dose
Study: NCT04049734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral losatan
Description: 50 mg of oral losartan one hour before the ERCP once
Study: NCT00159133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antipsychotics vs. Lorazepam (Drugs)
Description: Early intervention with low-dose antipsychotics vs. lorazepam (up to 3 mg/day) in case of early warning signs of an impending relapse;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antipsychotics vs. Lorazepam (Drugs)
Description: Early intervention with low-dose antipsychotics vs. lorazepam (up to 3 mg/day) in case of early warning signs of an impending relapse;
Study: NCT04369859

Intervention type: BEHAVIORAL
Intervention: Examine the impact of COVID-19 during pregnancy
Description: clinical data collection
Study: NCT02112032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.
Study: NCT01703650

Intervention type: DRUG
Intervention: iopromide
Description: 1. iopromide (370mgI/mL) enhanced perfusion CT will be performed within 14 days of operation.~2. In patients who are planned to receive chemotherapy, iopromide enhanced perfusion CT was performed twice; within 14 days before starting 1st cycle and within 14 days after finishing 2nd cycle.~3. iopromide (370mgI/mL) will be administered intravenously with an amount of 30mL (body weight\[BW\] \<50kg) or 35 mL (50kg ≤BW \<70kg) or 40 mL (70 kg≤BW \<90kg) or 50 mL (90≤BW), followed by saline infusion (30mL).~4. Injection rate is as follows; 6.0mL/sec if BW is \<50kg, 7.0 mL/sec if BW is 50kg≤and \<70kg, 8.0 mL/sec if BW is 70≤and\<90kg and 9.0mL/sec if BW is 90kg≤.

Intervention type: DRUG
Intervention: iopromide
Description: 1. iopromide (370mgI/mL) enhanced perfusion CT will be performed within 14 days of operation.~2. In patients who are planned to receive chemotherapy, iopromide enhanced perfusion CT was performed twice; within 14 days before starting 1st cycle and within 14 days after finishing 2nd cycle.~3. iopromide (370mgI/mL) will be administered intravenously with an amount of 30mL (body weight\[BW\] \<50kg) or 35 mL (50kg ≤BW \<70kg) or 40 mL (70 kg≤BW \<90kg) or 50 mL (90≤BW), followed by saline infusion (30mL).~4. Injection rate is as follows; 6.0mL/sec if BW is \<50kg, 7.0 mL/sec if BW is 50kg≤and \<70kg, 8.0 mL/sec if BW is 70≤and\<90kg and 9.0mL/sec if BW is 90kg≤.

Intervention type: PROCEDURE
Intervention: CT
Description: 1. Perfusion CT will be performed by using a 320 channel MDCT~2. Patients are requested for fasting for at least 8 hours before CT scan.~3. Patients are requested for doing shallow breathing as slow as possible and wide strap is applied during CT scan.~4. Scan range is limited to the whole pancreas and it focuses to the pancreas tumor lesion.~5. During perfusion CT, 19 phases (ten phases with two seconds interval and six phases with three seconds interval and three phases with five seconds interval) are obtained in fifty three seconds.~6. ADIR 3D and SURE EXPOSURE 3D are applied during perfusion CT to minimize radiation dose.

Intervention type: PROCEDURE
Intervention: CT
Description: 1. Perfusion CT will be performed by using a 320 channel MDCT~2. Patients are requested for fasting for at least 8 hours before CT scan.~3. Patients are requested for doing shallow breathing as slow as possible and wide strap is applied during CT scan.~4. Scan range is limited to the whole pancreas and it focuses to the pancreas tumor lesion.~5. During perfusion CT, 19 phases (ten phases with two seconds interval and six phases with three seconds interval and three phases with five seconds interval) are obtained in fifty three seconds.~6. ADIR 3D and SURE EXPOSURE 3D are applied during perfusion CT to minimize radiation dose.
Study: NCT03484845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin and ferrous fumarate
Description: * Group 1:include 50 women will receive oral lactoferrin 100mg twice daily .~* Group 2: include 50 women will receive oral Ferrous fumarate 30mg elemental iron twice daily .~* Group 3: include 50 women will receive oral combined lactoferrin 200mg and ferrous fumarate 60mg elemental iron once daily .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin and ferrous fumarate
Description: * Group 1:include 50 women will receive oral lactoferrin 100mg twice daily .~* Group 2: include 50 women will receive oral Ferrous fumarate 30mg elemental iron twice daily .~* Group 3: include 50 women will receive oral combined lactoferrin 200mg and ferrous fumarate 60mg elemental iron once daily .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin and ferrous fumarate
Description: * Group 1:include 50 women will receive oral lactoferrin 100mg twice daily .~* Group 2: include 50 women will receive oral Ferrous fumarate 30mg elemental iron twice daily .~* Group 3: include 50 women will receive oral combined lactoferrin 200mg and ferrous fumarate 60mg elemental iron once daily .
Study: NCT03029351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide Extended Release for Inj Susp 2 MG
Description: Exenatide extended release treatment weekly for 1 year in T2DM patients with micro- and macroalbuminuria

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo treatment weekly for 1 year in type 2 diabetes with micro-and macroalbuminuria
Study: NCT04027192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2328065 LSF
Description: 20 mg/mL LSF (liquid service formulation), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2328065 LSF
Description: 20 mg/mL LSF (liquid service formulation), orally
Study: NCT03603782

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D2: 5% protein 30 min before breakfast
Description: D2: 5% protein consumed 30 min before breakfast
Study: NCT01824238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anacetrapib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for anacetrapib
Study: NCT03243695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Angled Abutment
Description: virtual implants will be placed on a planning software allowing abutments to be placed at an angle to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The angled abutment will be placed and a temporary crown material will be fabricated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: straight abutment
Description: virtual implants will be placed on a planning software allowing abutments to be placed at straight to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The straight abutment will be placed and a temporary crown material will be fabricated.
Study: NCT02470286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 60mg or Placebo
Description: * Study Drug: SA001 60mg~* Comparator: Placebo~* Cohort 1 in the part 1 (Dose escalation study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 120mg or Placebo
Description: * Study Drug: SA001 120mg~* Comparator: Placebo~* Cohort 2 in the part 1 (Dose escalation study) and part 2 (Food effect study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 180mg or Placebo
Description: * Study Drug: SA001 180mg~* Comparator: Placebo~* Cohort 3 in the part 1 (Dose escalation study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 240mg or Placebo
Description: * Study Drug: SA001 240mg~* Comparator: Placebo~* Cohort 4 in the part 1 (Dose escalation study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 300mg or Placebo
Description: * Study Drug: SA001 300mg~* Comparator: Placebo~* Cohort 5 in the part 1(Dose escalation study) and part 2 (Food effect study)
Study: NCT02197884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911, 25 mg
Description: JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911, 25 mg
Description: JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Description: Itraconazole 200 mg (2\*100 mg capsule) orally once daily from Day 5 to Day 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg
Description: Clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
Study: NCT02230410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoBalloon Focal Ablation
Study: NCT00761423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP Injection with eccentric exercises
Description: PRP Injection with eccentric exercises

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection with eccentric exercises
Description: Placebo Injection with eccentric exercises
Study: NCT03907852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gavo-cel
Description: gavo-cel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gavo-cel
Description: gavo-cel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gavo-cel
Description: gavo-cel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: lymphodepletion chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: lymphodepletion chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: lymphodepletion chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: lymphodepletion chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: lymphodepletion chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: lymphodepletion chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: immuno-oncology agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: immuno-oncology agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: immuno-oncology agent